E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Venous Thrombotic Event |
Evento trombótico venoso |
|
E.1.1.1 | Medical condition in easily understood language |
Blood clots in the veins |
Coágulos de sangre en las venas. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066899 |
E.1.2 | Term | Venous thromboembolism |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This study is exploratory in nature and will investigate safety and tolerability of an oral liquid formulation of dabigatran etexilate in pediatric patients 1 to < 12 years old treated for primary VTE. The study will also provide preliminary pharmacokinetic and pharmacodynamic data for this age group. |
Este estudio es de naturaleza exploratoria e investigará la seguridad y tolerabilidad de una formulación líquida oral de dabigatrán etexilato en grupos sucesivos de pacientes pediátricos entre 2 y < 12 años de edad seguido de pacientes pediátricos de 1 a < 2 años de edad tratados por ETV. El estudio también proporcionará datos farmacocinéticos y farmacodinámicos preliminares para este grupo de edad. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Males or females 1 to < 12 years of age 2) Objective diagnosis of VTE 3) End of planned treatment course with low molecular weight heparin (LMWH) or oral anticoagulant (OAC) for VTE with INR and aPTT both within normal limits. 4) Written informed consent provided by the patient's parent (or legal guardian) and assent provided by the patient (if applicable) at the time of ICF signature. |
1) Niños de ambos sexos entre 1 y < 12 años de edad. 2) Diagnóstico objetivo de ETV. 3) Final del período de tratamiento planeado con heparina de bajo peso molecular (HBPM) o anticoagulante oral (AO) para ETV, con INR y TTPa ambos dentro de los límites de normalidad. 4) Consentimiento informado por escrito proporcionado por el progenitor (o tutor legal) del paciente y asentimiento del paciente (si procede) en el momento de la firma del FCI. |
|
E.4 | Principal exclusion criteria |
1) conditions associated with increased risk of bleeding 2) severe renal dysfunction or requirement for dialysis 3) active infective endocarditis 4) hepatic disease 5) anemia or thrombocytopenia 6) use of prohibited or restricted drug within previous week 7) pregnant females or females not using medically accepted contraceptive method 8) received investigational drug within past 30 days 9) unreliable patients or patients who have any condition that would not allow safe participation in study |
1) Patologías asociadas a un riesgo alto de hemorragia: 2) Insuficiencia renal grave o necesidad de diálisis 3) Endocarditis infecciosa activa 4) Enfermedad hepática: 5) Anemia o trombocitopenia. 6) Pacientes que han tomado algún tratamiento prohibido/medicación restringida/tratamiento en la semana anterior 7) Mujeres embarazadas o mujeres que no utilizan un método anticonceptivo aceptado médicamente.. 8) Pacientes que han recibido un fármaco en investigación en los últimos 30 días 9) Pacientes considerados no aptos por el investigador en lo referente al seguimiento durante el estudio o el cumplimiento de la administración del fármaco del estudio, o que tienen cualquier enfermedad que, en opinión del investigador, no permitiría una participación segura en el estudio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1) Incidence of all bleeding events, 2) Incidence of all adverse events. 3) Pharmacodynamic parameters: central and local measurement of TT 4) Pharmacokinetic parameters: plasma concentrations of total and free dabigatran, BIBR 1048 BS, BIBR 951BS, and BIBR 1087 SE, |
1) Incidencia de todos los episodios hemorrágicos 2) Incidencia de todos los acontecimientos adversos 3) Parámetros farmacodinámicos: medición central y local de TT 4) Parámetros farmacocinéticos: concentraciones plasmáticas de dabigatrán total y libre, BIBR 1048 BS, BIBR 951BS y BIBR 1087 SE. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Endpoints 1) & 2) measured during screening, treatment period and 30 day followup. Endpoints 3) & 4) measured during screening (baseline) and treatment period. |
Los criterios 1) y 2) se miden durante la selección, el periodo de tramiento y se realiza un seguimiento de 30 días. Los criterios 3) y 4) se miden durante la selección (periodo basal) y durante el periodo de tratamiento. |
|
E.5.2 | Secondary end point(s) |
1) Changes in laboratory and clinical parameters such as liver enzymes, ECG, and physical examination, 2) Occurrences of clinical outcomes including recurrent thrombosis, post thrombotic syndrome (PTS), pulmonary emboli (PEs), and total and venous thrombolic event (VTE) related mortality, 3)Global assessment of tolerability to study medication (including patient taste assessment), 4) Pharmacodynamic parameters: local measurement of aPTT. |
1) Cambios en los parámetros de laboratorio y clínicos como enzimas hepáticas, ECG y exploración física 2) Aparición de desenlaces clínicos como trombosis recurrente, síndrome postrombótico (SPT), embolia pulmonar (EP) y mortalidad total y relacionada con evento trombótico venoso (ETV) 3) Evaluación global de la tolerabilidad de la medicación del estudio (incluida la evaluación del sabor por el paciente). 4) Parámetros farmacodinámicos: medición local de TTPa. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Endpoints 1) to 3) measured during screening, treatment period and 30 day followup. Endpoint 4) measured during screening (baseline) and treatment period. |
Los criterios 1) al 3) se miden durante la selección, el tratamiento y durante un periodo de seguimiento de 30 días. El criterio 4) se mide durante la selección (periodo basal) y durante el periodo de tratamiento. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Austria |
Canada |
France |
Netherlands |
Switzerland |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Sixteen patients who have completed the 30 day post treatment followup period. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 0 |